Competitive Intelligence Platform · Biotech & Biopharma

Your team
knows first.

Competitive intelligence synthesized from USPTO filings, ClinicalTrials.gov, PubMed, and conference abstracts — available on demand. Self-serve access to the full data layer for BD, strategy, and legal teams.

Explore the platform →
Live signals
[USPTO]  US11,842,190 B2 · Roche · CDK4/6 binding domain (CPC: A61K31/519) · continuation of US10,988,477 · filed May 9, 2026 · [AACR 2026]  Abstract #4471 · AZ AZD-0156 Ph2 interim · BRCA1/2-mutant NSCLC · ORR 68% (95% CI 54–80) · n=74 · [ClinicalTrials.gov]  NCT06112840 · Novo Nordisk · Ph1 CDK2 inhibitor · added 6 sites · enrollment opened May 13 · [PubMed]  PMID 38901234 · Incyte INCB123667 + pembrolizumab · PD-L1 TPS ≥50% subgroup · Nat Med preprint · [EPO]  EP4389751A1 · Danish biotech · ATR kinase inhibitor · PCT application WO/2026/011832 · published Apr 14, 2026 · [ClinicalTrials.gov]  NCT05987341 · EGFR exon 19 del cohort · PFS 11.2 mo · status update May 14, 2026 · [USPTO]  US11,842,190 B2 · Roche · CDK4/6 binding domain (CPC: A61K31/519) · continuation of US10,988,477 · filed May 9, 2026 · [AACR 2026]  Abstract #4471 · AZ AZD-0156 Ph2 interim · BRCA1/2-mutant NSCLC · ORR 68% (95% CI 54–80) · n=74 · [ClinicalTrials.gov]  NCT06112840 · Novo Nordisk · Ph1 CDK2 inhibitor · added 6 sites · enrollment opened May 13 · [PubMed]  PMID 38901234 · Incyte INCB123667 + pembrolizumab · PD-L1 TPS ≥50% subgroup · Nat Med preprint · [EPO]  EP4389751A1 · Danish biotech · ATR kinase inhibitor · PCT application WO/2026/011832 · published Apr 14, 2026 · [ClinicalTrials.gov]  NCT05987341 · EGFR exon 19 del cohort · PFS 11.2 mo · status update May 14, 2026 ·
Veridian Bio Axelen Therapeutics Norvik Pharma Celtraline Brystage Sciences
0
Patents monitored weekly
USPTO + EPO OPS
0
Competitors tracked across 18 TAs
ClinicalTrials.gov + corporate filings
0
Clinical trial records parsed
ClinicalTrials.gov full-text
0
PubMed abstracts processed per week
PubMed / PMC + preprint servers
The platform

When a signal needs
investigation.

Self-serve access to the underlying data for analysts and BD teams. Pipeline landscapes, patent chains, and filing velocity — all in one place.

Pipeline Landscape CDK inhibitors · May 2026
Company Asset Stage Biomarker
Eli Lilly
 palbociclib
NCT01842775 · CDK4/6
HR+ BC · Updated May 2026
 Approved CDK4/6
Eli Lilly
 abemaciclib
NCT02246621 · CDK4/6
HR+ HER2- BC · Updated May 2026
 Approved CDK4/6
Pfizer
 ribociclib
NCT01958021 · CDK4/6
HR+ BC · Updated May 2026
 Approved CDK4/6
AstraZeneca
 AZD-0156
NCT05112244 · ATM/ATR
BRCA1/2+ NSCLC · Updated May 2026
 Phase 2 BRCA1/2
Roche
 RG7440
US11,842,190 B2
CDK4/6 · CPC A61K31/519
 Phase 2 CDK4/6
Incyte
 INCB123667
NCT05183906 · CDK2
PD-L1 TPS≥50% · PMID 38901234
 Phase 1 PD-L1 TPS
Novo Nordisk
 NNC0461-0006
NCT06112840 · CDK2
CDK2-amplified · 18 sites active
 Phase 1 CDK2-amp
Your program
 XYZ-001
NCT05987341 · CDK4/6
EGFR exon 19 del · Active
 Phase 2 EGFR ex19
Your program
 XYZ-002
US11,842,190 B2 (Roche)
FTO review recommended
 Preclinical CDK4/6
Patent Filing Velocity 2023 – 2026
Roche
AstraZeneca
Pfizer
Incyte
Data sourced from USPTO PatentsView API + EPO OPS
Filtered by CPC codes A61K31/519, A61P35/00, A61P35/02
Try the live demo →

Interactive · no login required · pre-loaded with oncology data

Data infrastructure

Built on public data

The signal has always been there. We built the pipeline to find it.

USPTO / PatentsView
Full-text claims, CPC codes, continuation chains, assignee changes, and Markush structure analysis.
↻ Daily · API + bulk download
"Detected Roche's 11th CDK4/6 continuation within 6 hours of USPTO publication."
EPO Open Patent Services
European filings, PCT applications, prior art search, inventor disambiguation across jurisdictions.
↻ Daily · OPS REST API
"EP4389751A1 linked Novo Nordisk's undisclosed CDK2 asset to a Copenhagen-based biotech via shared inventor graph."
ClinicalTrials.gov
Eligibility biomarker extraction (NLP), site additions, status changes, IND portfolio cross-referencing.
↻ Daily · CTGOV v2 API
"Caught Novo Nordisk's undisclosed CDK2 asset via site expansion pattern, 14 months before any press release."
PubMed / PMC
35M+ abstracts, citation graph traversal, preprint server links (bioRxiv, medRxiv), MeSH term extraction.
↻ Daily · E-utilities + FTP
"PMID 38901234 flagged 72h before journal publication via medRxiv DOI match."
ASCO / ESMO / AACR
Conference abstract servers scraped on embargo lift. 6–12 months ahead of journal publication for Phase 2/3 readouts.
↻ Per conference · Abstract PDF parse
"AACR 2026 Abstract #4471 (AZD-0156 ORR data) processed 4 minutes after embargo lift at 08:00 ET."
Methodology

From raw filing to
actionable brief.

01 — Monitor
Continuous data ingestion
USPTO, EPO, ClinicalTrials.gov, PubMed, and conference abstract servers — every 24 hours. 50,000+ records processed daily through structured extraction pipelines.
02 — Score
AI-assisted relevance ranking
Signals scored against your specific programs, biomarkers, and competitive set. Patent claims parsed for scope changes. Trial updates matched to your IND portfolio.
03 — Surface
Platform on demand
Analysts explore the full data layer anytime. Pipeline landscapes, patent continuation chains, and filing velocity — all queryable. Your IP counsel can filter to CPC-specific filing digests.
Pricing

Platform access.
Priced per team.

Platform
For analyst & BD teams
Self-serve access to the full competitive intelligence layer — pipeline landscapes, patent tracking, and filing velocity across your therapeutic areas.
  • Pipeline explorer (all TAs)
  • Patent landscape + continuation chains
  • Filing velocity charts (CPC-filtered)
  • IP risk alerts (USPTO + EPO)
  • Custom alerts · biomarker or entity
  • API access · JSON export